StockData
Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc. (ASMB) shareholders

ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/309% below fair value
$22.50+1.21 (+5.68%)

Close on Nov 17, 2026Market cap $458.11MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
92.1%
19M of 20M shares
Institutional holders
93
34 new, 15 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 13 sales
Net sold $252.33K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Gilead Sciences, Inc.4,977,08925.10%13D (active) amendmentMay 22, 2026
Commodore Capital LP
Joint filing with Commodore Capital Master LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more
1,615,9819.90%13G (passive)Aug 8, 2025
Saito Edric C.
Joint filing with Farallon Capital Management, L.L.C. (8.10%), Dapice Joshua J. (8.10%) and 13 more
1,604,5908.10%13G (passive) amendmentJun 30, 2026
Senai Asefaw, M.D.
Joint filing with Paradigm BioCapital Advisors LP (7.80%), Paradigm BioCapital Advisors GP LLC (7.80%) and 1 more
1,553,7487.80%13G (passive) amendmentJun 30, 2026
Peter Kolchinsky
Joint filing with RA Capital Management, L.P. (9.50%), Rajeev Shah (9.50%) and 1 more
1,530,6159.50%13G (passive)Aug 11, 2025
JANUS HENDERSON GROUP Ltd.1,359,5146.90%13G (passive) amendmentJun 30, 2026
Janus Henderson Group PLC1,341,5088.20%13G (passive)Nov 28, 2025
Dapice Joshua J.
Joint filing with Wehrly, Mark C. (7.80%), Dreyfuss, Philip D. (7.80%) and 13 more
1,227,5907.80%13G (passive) amendmentDec 31, 2025
Luo Patrick (Cheng)
Joint filing with Wehrly, Mark C. (7.30%), Dapice Joshua J. (7.30%) and 15 more
1,140,5107.30%13G (passive)Aug 8, 2025
Paradigm BioCapital Advisors GP LLC
Joint filing with Paradigm BioCapital Advisors LP (5.40%), Senai Asefaw, M.D. (5.40%)
865,2515.40%13G (passive)May 4, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ASMBValueChange% of portfolio
Gilead Sciences, Inc.4,977,08924.44%$136.77M+471,6988.30%
Farallon Capital Management LLC1,604,5907.88%$44.09M+377,0000.20%
Paradigm Biocapital Advisors LP1,553,7487.63%$42.70M+888,4970.80%
Commodore Capital LP1,415,0006.95%$38.88M+415,0002.32%
Ra Capital Management, L.P.1,020,4105.01%$28.04M–0.24%
Jupiter Topco LLC849,3094.17%$23.37MNew0.01%
BlackRock, Inc.766,8193.77%$21.07M+564,0760.00%
Parkman Healthcare Partners LLC721,1813.54%$19.82M+309,9542.03%
Vanguard Capital Management LLC558,9422.75%$15.36M+68,4950.00%
Point72 Asset Management, L.P.460,5932.26%$12.66M+116,4880.01%
Seven Fleet Capital Management LP433,1472.13%$11.90M+377,0001.96%
Millennium Management LLC298,8071.47%$8.21M+65,1570.00%
Geode Capital Management, LLC280,4241.38%$7.71M+147,4530.00%
Schonfeld Strategic Advisors LLC242,1531.19%$6.65M+121,6530.02%
Ameriprise Financial Inc230,0001.13%$6.32MNew0.00%
Dv Equities, LLC226,4151.11%$6.22MNew0.89%
abrdn plc207,0471.02%$5.69MNew0.01%
Affinity Asset Advisors, LLC190,0000.93%$5.22MNew0.24%
B Group, Inc.175,7060.86%$4.83M–2.27%
State Street Corp171,9310.84%$4.72M+115,2420.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20269319M92.1%34 / 3517 / 157M1M
Q1 20267514M67.6%17 / 2817 / 102M1M
Q4 20256914M67.4%22 / 2313 / 82M1M
Q3 20255712M61.3%31 / 163 / 79M0M
Q2 2025333M15.5%5 / 78 / 90M0M
Q1 2025373M15.6%6 / 1110 / 40M0M
Q4 2024353M15.6%10 / 117 / 52M0M
Q3 2024301M5.1%5 / 87 / 10M0M
Q2 2024271M5.8%5 / 96 / 21M0M
Q1 2024241M3.2%0 / 109 / 210M0M
Q4 2023451M3.6%17 / 97 / 40M0M
Q3 2023321M4.0%2 / 312 / 20M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

63 funds held ASMB in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ASMBValue% of fundAs of
Vanguard Total Stock Market Index Fund413,2842.03%$11.36M0.00%Jun 30, 2026
iShares Russell 2000 ETF244,9941.20%$6.73M0.01%Jun 30, 2026
Vanguard Extended Market Index Fund133,2920.65%$3.66M0.00%Jun 30, 2026
Fidelity Small Cap Index Fund107,3860.53%$2.70M0.01%Jul 31, 2026
iShares Russell 2000 Value ETF89,2710.44%$2.45M0.02%Jun 30, 2026
Fidelity Extended Market Index Fund58,3960.29%$1.62M0.00%May 31, 2026
Franklin Biotechnology Discovery Fund40,9820.20%$1.03M0.09%Jul 31, 2026
iShares Micro-Cap ETF33,1350.16%$910.55K0.06%Jun 30, 2026
Schwab Small-Cap Index Fund23,7810.12%$597.14K0.01%Jul 31, 2026
Fidelity Total Market Index Fund21,2520.10%$587.83K0.00%May 31, 2026
Small Cap Value Fund20,7280.10%$569.61K0.08%Jun 30, 2026
Master Small Cap Index Series18,4250.09%$506.32K0.01%Jun 30, 2026
Fidelity Series Total Market Index Fund16,9170.08%$467.92K0.00%May 31, 2026
Fidelity Small Cap Value Index Fund13,7500.07%$377.85K0.02%Jun 30, 2026
Virtus Biotech Clinical Trials Etf13,5370.07%$339.91K0.73%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jason A. OkazakiCEO and President, Director195,5320.96%Nov 3, 2026
Jeanette M. BjorkquistPFO and PAO17,6730.09%Nov 3, 2026
William E. Delaney IVChief Scientific Officer74,0350.36%Nov 3, 2026
Anuj GaggarChief Medical Officer53,8000.26%Nov 3, 2026
Nicole S. WhiteChief Manufacturing Officer59,2570.29%Nov 3, 2026
Susan MahonyDirector––Jun 5, 2026
Lisa Johnson-PrattDirector––Jun 5, 2026
Michael HoughtonDirector3,2020.02%Jun 5, 2026
Anthony E. AltigDirector8,0000.04%Jun 5, 2026
Gina ConsylmanDirector––Jun 5, 2026
John G. McHutchisonDirector18,3470.09%Jun 5, 2026
William R. RingoDirector17,4650.09%Jun 9, 2025
Gilead Sciences, Inc.10% owner4,977,08924.44%May 27, 2026
Alexander Schornstein10% owner1,832,4059.00%Nov 26, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jeanette M. Bjorkquist
PFO and PAO
Nov 2, 2026Sale−9$20.35$18317,673
Jeanette M. Bjorkquist
PFO and PAO
Nov 2, 2026Sale−718$19.61$14.08K17,682
Nicole S. White
Chief Manufacturing Officer
Nov 2, 2026Sale−29$20.35$59059,257
Nicole S. White
Chief Manufacturing Officer
Nov 2, 2026Sale−2,564$19.61$50.27K59,286
Anuj Gaggar
Chief Medical Officer
Nov 2, 2026Sale−29$20.35$59053,800
Anuj Gaggar
Chief Medical Officer
Nov 2, 2026Sale−2,564$19.61$50.27K53,829
Jason A. Okazaki
CEO and President, Director
Nov 2, 2026Sale−69$20.35$1.40K195,532
Jason A. Okazaki
CEO and President, Director
Nov 2, 2026Sale−6,133$19.61$120.25K195,601
Jeanette M. Bjorkquist
PFO and PAO
Oct 30, 2026Award+3,840––18,400
Nicole S. White
Chief Manufacturing Officer
Oct 30, 2026Award+13,705––61,850
William E. Delaney IV
Chief Scientific Officer
Oct 30, 2026Award+13,705––74,035
Anuj Gaggar
Chief Medical Officer
Oct 30, 2026Award+13,705––56,393
Jason A. Okazaki
CEO and President, Director
Oct 30, 2026Award+38,380––201,734
Jeanette M. Bjorkquist
PFO and PAO
Jun 17, 2026Sale−29$23.25$67414,560
Gilead Sciences, Inc.
10% owner
May 26, 2026Award+471,698$26.50$12.50M4,977,089
Jeanette M. Bjorkquist
PFO and PAO
Mar 30, 2026Sale−312$26.65$8.31K11,105
Jeanette M. Bjorkquist
PFO and PAO
Mar 30, 2026Sale−16$27.49$44011,089
Nicole S. White
Chief Manufacturing Officer
Mar 30, 2026Sale−188$26.65$5.01K37,486
Nicole S. White
Chief Manufacturing Officer
Mar 30, 2026Sale−9$27.49$24737,477
William E. Delaney IV
Chief Scientific Officer
Mar 29, 2026Award+14,000––60,330
Anuj Gaggar
Chief Medical Officer
Mar 29, 2026Award+14,000––42,688
Jeanette M. Bjorkquist
PFO and PAO
Mar 29, 2026Award+3,500––14,589
Nicole S. White
Chief Manufacturing Officer
Mar 29, 2026Award+14,000––48,145
Jason A. Okazaki
CEO and President, Director
Mar 29, 2026Award+50,750––163,354
Jeanette M. Bjorkquist
PFO and PAO
Mar 29, 2026Award+6,500––11,417
Nicole S. White
Chief Manufacturing Officer
Mar 29, 2026Award+26,000––37,674
William E. Delaney IV
Chief Scientific Officer
Mar 29, 2026Award+26,000––45,642
Jason A. Okazaki
CEO and President, Director
Mar 29, 2026Award+94,250––111,916
Anuj Gaggar
Chief Medical Officer
Mar 29, 2026Award+26,000––28,000
Gilead Sciences, Inc.
10% owner
Aug 8, 2025Buy+2,295,920––4,505,391
Jeanette M. Bjorkquist
PFO and PAO
Jun 16, 2025Award+300––5,097
John G. McHutchison
Director
Mar 31, 2025Sale−757$9.85$7.46K18,347
Jeanette M. Bjorkquist
Principal Accounting Officer
Mar 31, 2025Sale−180$9.85$1.77K4,617
Nicole S. White
Chief Manufacturing Officer
Mar 31, 2025Sale−197$9.85$1.94K11,674
Jason A. Okazaki
CEO and President, Director
Mar 31, 2025Sale−355$9.85$3.50K14,757
Jeanette M. Bjorkquist
Principal Accounting Officer
Mar 29, 2025Award+1,655––4,797
Michael Houghton
Director
Dec 30, 2024Buy+3,202$15.61$49.98K3,202
Gilead Sciences, Inc.
10% owner
Dec 19, 2024Buy+940,499$21.37$20.10M2,209,471
Alexander Schornstein
10% owner
Nov 25, 2024Buy+5,000$14.85$74.25K728,113
Alexander Schornstein
10% owner
Nov 25, 2024Buy+2,976$15.00$44.64K723,113
Alexander Schornstein
10% owner
Nov 22, 2024Buy+17,024$14.87$253.15K720,137
Nicole S. White
Chief Manufacturing Officer
Nov 18, 2024Sale−40$16.29$65211,871
Alexander Schornstein
10% owner
Oct 8, 2024Buy+10,000$14.58$145.80K703,113
Nicole S. White
Chief Manufacturing Officer
Oct 3, 2024Sale−157$14.81$2.33K11,911
Jason A. Okazaki
CEO and President, Director
Oct 3, 2024Sale−197$14.81$2.92K14,904
Jason A. Okazaki
CEO and President, Director
Aug 2, 2024Sale−981$14.23$13.96K15,101
Nicole S. White
Chief Manufacturing Officer
Aug 2, 2024Sale−785$14.23$11.17K12,068
Alexander Schornstein
10% owner
Jul 5, 2024Buy+4,438$12.52$55.56K693,113
Alexander Schornstein
10% owner
Jul 3, 2024Buy+4,562$12.29$56.07K688,675
Gilead Sciences, Inc.
10% owner
Jun 17, 2024Buy+179,500––1,268,972
John G. McHutchison
Director
May 23, 2024Sale−2,117$14.93$31.61K19,104
Jeanette M. Bjorkquist
Principal Accounting Officer
May 23, 2024Sale−24$14.93$3583,142
Jason A. Okazaki
CEO and President, Director
May 23, 2024Sale−549$14.93$8.20K16,082
Nicole S. White
Chief Manufacturing Officer
May 23, 2024Sale−172$14.93$2.57K12,853
Nicole S. White
Chief Manufacturing Officer
Apr 30, 2024Sale−1,255$12.71$15.95K13,025
Jason A. Okazaki
CEO and President, Director
Apr 30, 2024Sale−1,569$12.71$19.94K16,423
Nicole S. White
Chief Manufacturing Officer
Apr 29, 2024Award+3,333––14,280
Jason A. Okazaki
CEO and President, Director
Apr 29, 2024Award+4,166––17,992
William E. Delaney IV
Chief Scientific Officer
Apr 29, 2024Award+3,333––16,109
Nicole S. White
Chief Manufacturing Officer
Apr 1, 2024Sale−197$13.07$2.57K10,947

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
21.07%
3M shares short
Days to cover
17.0
At 0M shares a day
Change since last report
+4.1%
From 3M shares
Short volume, 20 days
61.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Assembly Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,727 shares on Aug 31, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Nicole S. White
Officer
Nov 2, 20262,593$50.86KNov 2, 2026Restricted Stock Unit Release
Anuj Gaggar
Officer
Nov 2, 20262,593$50.86KNov 2, 2026Restricted Stock Unit Release
Jason A. Okazaki
Officer, Director
Nov 2, 20266,202$121.66KNov 2, 2026Restricted Stock Unit Release
Jason A. Okazaki
Officer, Director
Oct 3, 20232,363$2.01KOct 3, 2023Restricted Stock Unit Release
William E. Delaney IV
Officer
Oct 3, 20231,891$1.61KOct 3, 2023Restricted Stock Unit Release
Jason A. Okazaki
Officer, Director
Aug 2, 202311,827$12.87KAug 2, 2023Restricted Stock Unit Release
William E. Delaney IV
Officer
Aug 2, 20239,461$10.29KAug 2, 2023Restricted Stock Unit Release
William E. Delaney IV
Officer
May 30, 20234,232$4.05KMay 30, 2023Restricted Stock Unit Release
John G. McHutchison
Director
May 23, 202325,972$27.02KMay 23, 2023Restricted Stock Unit Release
William E. Delaney IV
Officer
May 23, 20236,561$6.83KMay 23, 2023Restricted Stock Unit Release
Jason A. Okazaki
Officer, Director
May 23, 20236,561$6.83KMay 23, 2023Restricted Stock Unit Release

Congress trades

2 trades in Assembly Biosciences reported by 1 member of the House

MemberTypeTradedAmountFiled
Christopher L. Jacobs
NY27
SoldJan 4, 2021$1K–15KFeb 17, 2021
Christopher L. Jacobs
NY27
BoughtDec 28, 2020$1K–15KFeb 10, 2021

See a number that looks wrong?